Pfizer selects Catalent to make Nexium from expanded Kentucky plant
Catalent will manufacture a heartburn OTC treatment for Pfizer from its newly expanded facility in Kentucky.
Catalent will manufacture a heartburn OTC treatment for Pfizer from its newly expanded facility in Kentucky.
Preclinical CRO Crown Bioscience will further increase capacity across its UK facilities to support demand for syngeneic models.
Aptuit plans to up tabletting and encapsulation capacity at sites in the UK and Italy less than a year after it increased API output at the same facilities.
Janssen has teamed up with Cypralis to target neurodegenerative diseases through the development of cyclophilin inhibitors.
AMRI has opened a drug discovery center, citing growing customer demand for biology, high-throughput screening, in vitro pharmacology, and medicinal chemistry at a single site.
Salary increases will only help CROs hold on to staff for so long according to the author of a wages study who says retention is ultimately about building loyalty.